PriceTargets.com logo

R1 RCM - rcm Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $15.73
  • Forecasted Upside: 9.91%
  • Number of Analysts: 17
  • Breakdown:
  • 0 Sell Ratings
  • 12 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$14.31 As of 11/19/2024 09:00 PM ET
▲ +0.01 (0.07%)
Get New R1 RCM Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RCM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RCM

Analyst Price Target is $15.73
▲ +9.91% Upside Potential
This price target is based on 17 analysts offering 12 month price targets for R1 RCM in the last 3 months. The average price target is $15.73, with a high forecast of $19.00 and a low forecast of $14.00. The average price target represents a 9.91% upside from the last price of $14.31.

This chart shows the closing price for RCM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 17 polled investment analysts is to hold stock in R1 RCM. This rating has held steady since July 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/2/2023
  • 0 strong buy ratings
  • 14 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2023
  • 0 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/29/2023
  • 0 strong buy ratings
  • 12 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
3/28/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 13 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 13 hold ratings
  • 0 sell ratings
Ratings as of
11/23/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 12 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 12 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/4/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$14.30 ➝ $14.30
8/20/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$14.30 ➝ $14.30
8/8/2024Truist FinancialLower TargetHold ➝ Hold$16.00 ➝ $14.30
8/8/2024Morgan StanleyDowngradeOverweight ➝ Equal Weight
8/5/2024TD CowenReiterated RatingBuy ➝ Hold$20.00 ➝ $14.30
8/2/2024Cantor FitzgeraldDowngradeStrong-Buy ➝ Hold
8/1/2024Leerink PartnrsDowngradeStrong-Buy ➝ Hold
8/1/2024StephensDowngradeOverweight ➝ Equal Weight
8/1/2024Leerink PartnersDowngradeOutperform ➝ Market Perform$17.00 ➝ $14.30
8/1/2024Jefferies Financial GroupDowngradeBuy ➝ Hold
7/22/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
7/9/2024Deutsche Bank AktiengesellschaftBoost TargetHold ➝ Hold$14.00 ➝ $16.00
7/8/2024Morgan StanleyReiterated RatingOverweight ➝ Overweight$17.00 ➝ $17.00
7/2/2024Robert W. BairdReiterated RatingOutperform ➝ Outperform$18.00 ➝ $18.00
7/2/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$20.00 ➝ $20.00
6/28/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$19.00 ➝ $19.00
6/11/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$19.00 ➝ $19.00
5/9/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$16.00 ➝ $15.00
4/10/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$20.00
4/10/2024KeyCorpReiterated RatingOverweight ➝ Sector Weight
4/5/2024GuggenheimLower TargetBuy ➝ Buy$17.00 ➝ $15.00
4/1/2024Truist FinancialReiterated RatingHold ➝ Hold$16.00
3/26/2024Morgan StanleyReiterated RatingOverweight ➝ Overweight$17.00
3/20/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$17.00 ➝ $16.00
3/20/2024CitigroupUpgradeNeutral ➝ Buy$16.00
3/7/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$19.00
3/5/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$20.00
3/5/2024Truist FinancialReiterated RatingBuy ➝ Hold$16.00
3/1/2024CitigroupBoost TargetBuy ➝ Buy$14.00 ➝ $16.00
2/29/2024KeyCorpBoost TargetOverweight ➝ Overweight$13.00 ➝ $17.00
2/28/2024Evercore ISIReiterated RatingOutperform ➝ In-Line$12.00 ➝ $16.00
2/28/2024BarclaysReiterated RatingOverweight ➝ Equal Weight$14.00
2/26/2024Leerink PartnrsReiterated RatingOutperform
2/26/2024Leerink PartnersInitiated CoverageOutperform$14.00
1/5/2024KeyCorpLower TargetOverweight ➝ Overweight$18.00 ➝ $13.00
1/3/2024BarclaysInitiated CoverageOverweight$14.00
12/15/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight$17.50 ➝ $17.00
12/13/2023JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$20.00 ➝ $11.00
12/7/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$19.00
12/7/2023Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$17.00
12/4/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$20.00
11/3/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$22.00 ➝ $19.00
11/3/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$19.00 ➝ $17.50
11/3/2023KeyCorpLower TargetOverweight ➝ Overweight$20.00 ➝ $18.00
10/19/2023Truist FinancialUpgradeHold ➝ Buy$18.00
10/11/2023Evercore ISILower Target$21.00 ➝ $20.00
9/22/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$22.00
9/22/2023CitigroupInitiated CoverageBuy$20.00
8/15/2023Cantor FitzgeraldInitiated CoverageOverweight$20.00
8/3/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$16.00 ➝ $19.00
8/3/2023BarclaysBoost TargetOverweight ➝ Overweight$18.00 ➝ $20.00
7/21/2023GuggenheimReiterated RatingBuy ➝ Buy$21.00
6/16/2023Jefferies Financial GroupBoost Target$20.00 ➝ $22.00
6/15/2023Royal Bank of CanadaBoost Target$18.00 ➝ $22.00
5/19/2023Bank of AmericaBoost Target$19.00 ➝ $22.00
5/8/2023Deutsche Bank AktiengesellschaftBoost Target$16.00 ➝ $18.00
4/13/2023Bank of AmericaBoost TargetBuy$17.50 ➝ $19.00
4/11/2023StephensInitiated CoverageOverweight$18.00
4/11/2023Robert W. BairdInitiated CoverageOutperform$18.00
2/17/2023Canaccord Genuity GroupBoost TargetBuy$17.00 ➝ $21.00
2/17/2023Deutsche Bank AktiengesellschaftBoost Target$14.00 ➝ $16.00
2/2/2023Royal Bank of CanadaBoost TargetOutperform$14.00 ➝ $18.00
2/2/2023KeyCorpBoost TargetOverweight$15.00 ➝ $20.00
2/2/2023Truist FinancialDowngradeBuy ➝ Hold$15.00
1/18/2023BarclaysBoost TargetOverweight$12.00 ➝ $16.00
1/5/2023Canaccord Genuity GroupInitiated CoverageBuy$14.00
12/7/2022GuggenheimUpgradeNeutral ➝ Buy$15.00
12/6/2022Royal Bank of CanadaBoost TargetOutperform$12.00 ➝ $14.00
12/6/2022Morgan StanleyInitiated CoverageEqual Weight$11.00
12/5/2022KeyCorpBoost TargetOverweight$10.00 ➝ $15.00
11/18/2022JPMorgan Chase & Co.Lower TargetOverweight$33.00 ➝ $11.00
11/15/2022Evercore ISILower Target$10.00
11/15/2022BarclaysLower Target$12.00
11/14/2022CowenLower Target$34.00 ➝ $25.00
11/14/2022CowenLower TargetOutperform$34.00 ➝ $25.00
11/10/2022Deutsche Bank AktiengesellschaftLower Target$31.00 ➝ $14.00
11/9/2022Leerink PartnersLower TargetOutperform$35.00 ➝ $16.00
11/9/2022Royal Bank of CanadaLower TargetOutperform$35.00 ➝ $12.00
11/9/2022KeyCorpLower TargetOverweight$30.00 ➝ $10.00
10/23/2022Evercore ISIInitiated CoverageOutperform$25.00
9/15/2022KeyCorpInitiated CoverageOverweight$30.00
9/7/2022Truist FinancialInitiated CoverageBuy$29.00
8/4/2022Deutsche Bank AktiengesellschaftBoost Target$26.00 ➝ $31.00
8/1/2022JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight
6/29/2022Deutsche Bank AktiengesellschaftLower TargetBuy$28.00 ➝ $26.00
6/29/2022BarclaysReiterated RatingOverweight ➝ Overweight$29.00
5/10/2022Deutsche Bank AktiengesellschaftLower Target$30.00 ➝ $28.00
4/13/2022GuggenheimInitiated CoverageNeutral
3/3/2022Robert W. BairdBoost Target$29.00 ➝ $32.00
2/9/2022Deutsche Bank AktiengesellschaftInitiated CoverageBuy$30.00
12/13/2021CowenLower TargetOutperform ➝ Outperform$37.00 ➝ $34.00
12/1/2021Jefferies Financial GroupInitiated CoverageBuy$28.00
10/14/2021JPMorgan Chase & Co.Initiated CoverageOverweight$27.00
9/30/2021BarclaysInitiated CoverageOverweight$28.00
8/19/2021Robert W. BairdReiterated RatingBuy
7/22/2021Bank of AmericaInitiated CoverageBuy$27.00
6/2/2021Robert W. BairdInitiated CoverageOutperform$30.00
5/27/2021Leerink PartnersReiterated RatingBuy
2/16/2021KeyCorpBoost Target$27.00 ➝ $35.00
2/9/2021CowenBoost TargetOutperform$22.00 ➝ $33.00
1/6/2021KeyCorpBoost TargetOverweight$24.00 ➝ $26.00
12/9/2020Royal Bank of CanadaBoost TargetOutperform$20.00 ➝ $27.00
12/3/2020Leerink PartnersBoost TargetOutperform$22.00 ➝ $26.00
11/4/2020Cantor FitzgeraldBoost TargetOverweight$18.00 ➝ $22.00
11/4/2020Leerink PartnersBoost TargetOutperform$18.00 ➝ $22.00
11/2/2020KeyCorpBoost TargetOverweight$17.00 ➝ $24.00
8/5/2020Leerink PartnersUpgradeMarket Perform ➝ Outperform$14.00 ➝ $18.00
7/14/2020KeyCorpBoost TargetOverweight$12.00 ➝ $15.00
4/20/2020Royal Bank of CanadaInitiated CoverageOutperform$12.00
4/13/2020Leerink PartnersInitiated CoverageMarket Perform$10.00
1/21/2020Cantor FitzgeraldReiterated RatingOverweight$15.00 ➝ $17.00
1/14/2020KeyCorpBoost TargetOverweight$14.00 ➝ $15.00
1/10/2020Dougherty & CoInitiated CoverageBuy$15.00
(Data available from 12/23/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 14 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
5/27/2024
  • 11 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/26/2024
  • 8 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/26/2024
  • 9 very positive mentions
  • 27 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/25/2024
  • 12 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/24/2024
  • 10 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/24/2024
  • 7 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/23/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
R1 RCM logo
R1 RCM Inc. provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers. The company also offers modular solutions, including functional partnership, an outsourcing solutions for improvements across targeted revenue cycle areas for hospital and physician group customers; revenue recovery, to fast-track payer and patient cash collections; revenue optimization, a solution to uncover missed or underreported revenue; clinical integrity, used to improve documentation and coding accuracy to maximize earned revenue for the services provided; and regulatory navigation, a compliance-first solutions for government reimbursement accuracy, pharmacy savings, and compliance. The company was incorporated in 2003 and is headquartered in Murray, Utah.
Read More

Today's Range

Now: $14.31
Low: $14.30
High: $14.32

50 Day Range

MA: $14.28
Low: $14.20
High: $14.31

52 Week Range

Now: $14.31
Low: $8.87
High: $15.12

Volume

13,784,800 shs

Average Volume

3,577,960 shs

Market Capitalization

$6.04 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84

Frequently Asked Questions

What sell-side analysts currently cover shares of R1 RCM?

The following sell-side analysts have issued stock ratings on R1 RCM in the last twelve months: Barclays PLC, Canaccord Genuity Group Inc., Cantor Fitzgerald, Citigroup Inc., Deutsche Bank Aktiengesellschaft, Evercore ISI, Guggenheim, Jefferies Financial Group Inc., KeyCorp, Leerink Partners, Leerink Partnrs, Morgan Stanley, Robert W. Baird, Royal Bank of Canada, Stephens, TD Cowen, and Truist Financial Co..
View the latest analyst ratings for RCM.

What is the current price target for R1 RCM?

0 Wall Street analysts have set twelve-month price targets for R1 RCM in the last year. Their average twelve-month price target is $15.73, suggesting a possible upside of 9.9%. Royal Bank of Canada has the highest price target set, predicting RCM will reach $19.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $14.00 for R1 RCM in the next year.
View the latest price targets for RCM.

What is the current consensus analyst rating for R1 RCM?

R1 RCM currently has 12 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in RCM, but not buy more shares or sell existing shares.
View the latest ratings for RCM.

What other companies compete with R1 RCM?

Other companies that are similar to R1 RCM include Laboratory Co. of America, Quest Diagnostics, DaVita, Chemed and CorVel. Learn More about companies similar to R1 RCM.

How do I contact R1 RCM's investor relations team?

R1 RCM's physical mailing address is 401 NORTH MICHIGAN AVENUE SUITE 2700, CHICAGO IL, 60611. The healthcare provider's listed phone number is (312) 324-7820 and its investor relations email address is [email protected]. The official website for R1 RCM is www.r1rcm.com. Learn More about contacing R1 RCM investor relations.